Recent Headlines
Within Biotechnology
Gallant Announces Hiring of John Klacking, Ph.D. as Chief Business Officer
Furthering its regenerative medicine therapeutics research and development, animal biotech company Gallant welcomes a pioneer in the biotech space. - October 25, 2022 - Gallant
Huntington Study Group Announces Results from the HD-Net Assessment on the State of Care for Huntington’s Disease in the United States
The Huntington Study Group (HSG), a world leader in clinical research for Huntington’s Disease (HD) for over 30 years, is pleased to announce the results from the novel HD-Net survey, which examined the United States Huntington’s disease (HD) care delivery in a variety of clinic settings by HD specialists and non-specialists. - October 25, 2022 - Huntington Study Group
Minus K Technology Announces Announces Its Seventh U.S. Educational Giveaway of Vibration Isolators to Colleges and Universities
As Minus K celebrates their upcoming 30 years in business, they are giving away $25,000* dollars worth of passive mechanical patented superior performing negative-stiffness low-frequency vibration isolators to colleges in the United States. - October 25, 2022 - Minus K Technology Inc.
Vivisum Partners Publishes Strategic Analysis on the Ulcerative Colitis Marketplace
Among branded ulcerative colitis treatments, 84% of US gastroenterologists expect Zeposia to see an increase in prescription volume over the next 12 months, according to new research on the ulcerative colitis marketplace published by Vivisum Partners. Vivisum Partners has just published its... - October 25, 2022 - Vivisum Partners, LLC
New Market Insights on the Best MS Treatment Published by Vivisum Partners
What’s the best MS treatment according to neurologists? The question of how to assess the ideal drug to treat multiple sclerosis is difficult to answer. Neurologists determine which clinical attributes take higher priority for each patient. Vivisum Partners, LLC, a market research firm in... - October 24, 2022 - Vivisum Partners, LLC
Creative Diagnostics Introduces Fluorometric Neuraminidase Assay Service for High-Throughput Discovery
As an expert in the antiviral field providing solutions to assist virology and microbiology research, Creative Diagnostics recently introduced Fluorometric Neuraminidase Assay services to the global research community, suitable for functional detection of NI-resistant viruses in mixed virus... - October 23, 2022 - Creative Diagnostics
Creative Diagnostics Launches Monkeypox Virus Antigens and Antibodies to Accelerate MPXV Study
Creative Diagnostics announced the launch of Monkeypox Virus Antigens and Antibodies to support scientists focused on the research of monkeypox virus. - October 23, 2022 - Creative Diagnostics
Huntington Study Group Announces myHDstory™ Pilot Study: Making HD Voices Heard Has Reached Target Enrollment
The Huntington Study Group (HSG), a world leader in clinical research for Huntington’s Disease (HD) for over 30 years, is pleased to announce that the pilot study, Making HD Voices Heard, on the new online research platform, myHDstory™, has reached its enrollment target. “The HSG... - October 18, 2022 - Huntington Study Group
Biolexis Therapeutics Announces Launch of FIELDS, an AI/ML Drug Discovery Platform
Biolexis is the first company to combine a curated historical wet-lab database, including half-a-million targets of binding data points, with an automated AI/ML-augmented discovery platform. - October 14, 2022 - Biolexis Therapeutics Inc.
Thrivous Releases Serenity Nightly Nootropic Formula 3
Thrivous, the human enhancement company, has released Serenity Nightly Nootropic Formula 3 with KSM-66® Ashwagandha. Serenity is the advanced nootropic supplement that Thrivous develops to enhance relaxation, sleep, and next-day focus. Serenity combines nootropic nutrients with the highest... - October 14, 2022 - Thrivous
Huntington Study Group Enrolls First Participant for Its Observational Study to Test the Reliability of the Virtual Use of the Unified Huntington’s Disease Rating Scale
The Huntington Study Group (HSG), a world leader in conducting clinical trials for Huntington’s Disease (HD) for over 30 years, together with its Clinical Research Organization (“CRO”), the HSG Clinical Research, Inc., today announces the enrollment of the first participant of its... - October 12, 2022 - Huntington Study Group
Mirror Biologics, Inc. Announces Additional $20 Million Investment to Close Out $30 Million Series A Investment Round
Mirror Biologics, Inc., a clinical stage biopharmaceutical company today announced the completion of the final $20 million tranche of its $30 million Series A investment round with Bradbury Asset Management (Hong Kong), Limited. Bradbury provided an initial $10 million tranche for this round in... - October 11, 2022 - Mirror Biologics, Inc.
SYNG Pharmaceuticals Announces Issuance of Its Canadian Patent for Non-Hormonal Therapy for Endometriosis
SYNG Pharmaceuticals Inc. (SYNG), a Kingston, Ontario based women’s health biotech, is pleased to announce that on October 04, 2022, the Canadian Intellectual Property Office granted Canada Patent No. 2,903,608 titled, "Treatment of endometriosis, angiogenesis and/or endometrial lesion growth." - October 09, 2022 - SYNG Pharmaceuticals Inc.
Vivisum Partners' Research Finds New Ulcerative Colitis Drugs Provide Excitement to Gastroenterologists
Newly published research found that several new ulcerative colitis drugs currently in development are providing excitement among gastroenterologists eager to add additional medicines to their current treatment options. Based on a market analysis from Vivisum Partners, a market research and brand... - October 08, 2022 - Vivisum Partners, LLC
Evidence Partners Rebrands as DistillerSR to Leverage Market Awareness of Its Core Literature Review Platform
The Company Also Bolstered Its Executive Team in Security, Product Management and Operations to Support Accelerating Growth - September 28, 2022 - DistillerSR
ALS Therapy Development Institute Announces Superior Rail & Iron Works, Inc. as First Title Sponsor of White Coat Affair Gala
Superior Rail & Iron Works, Inc. will be the first Title Sponsor of the White Coat Affair gala, being held on October 15, 2022, at the Boston Sheraton to raise funds for ALS research. - September 28, 2022 - ALS Therapy Development Institute
Creative Diagnostics Announces the Launch of SARS-CoV-2 ADE Assay
Creative Diagnostics announced the launch of SARS-CoV-2 ADE Assay to support laboratory scientists for SARS-CoV-2 vaccine research. - September 28, 2022 - Creative Diagnostics
Creative Diagnostics Introduces Highly Sensitive Cytopathic Effect Inhibition Assay Service
Creative Diagnostics introduced the Cytopathic Effect Inhibition Assay Service of high assay sensitivity and accuracy. - September 28, 2022 - Creative Diagnostics
NuvOx Appoints Dr. Katy Peters to SAB
NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, appointed Dr. Katy Peters to its Scientific Advisory Board (SAB). Dr. Katy Peters, MD, Ph.D. FAAN is an associate professor of neurology and... - September 22, 2022 - NuvOx Therapeutics
New Decentralized Clinical Trial (DCT) Patient Satisfaction and Participation Report
800 Current and Future Clinical Trial Participants Link Satisfaction and Willingness to Participate with Decentralized Strategies - September 21, 2022 - Life Science Strategy Group, LLC
Biomed Industries, Inc. to Acquire MedAware Systems, Inc. to Expand Its Artificial Intelligence Research for Drug Discovery in Alzheimer’s Disease
Biomed Industries, Inc. (“BIOMED” or the “Company”), has entered into a share exchange agreement to acquire all of the issued and outstanding shares of MedAware Systems, Inc. MedAware shares was valued at $1.50 per share and BIOMED’s share was valued at $8.00 per share. The transaction was valued at an aggregate of $18 million, to be paid in the form of 2,259,170 common shares of BIOMED. On the date of the Agreement, BIOMED has approximately 76,354,075 common shares. - September 21, 2022 - Biomed Industries, Inc.
Serpin Pharma Awarded Competitive NCI Grant for SP16
The National Cancer Institute awarded Serpin Pharma a $400,000 competitive R43 grant for the Pre-clinical validation of phase II peptide LRP-1 agonist to treat and prevent chemotherapy-induced peripheral neuropathy. The Principal Investigators are Serpin Pharma's CEO and Executive Chairperson, Dr. - September 20, 2022 - Serpin Pharma, LLC
Paras Biopharmaceuticals Finland Oy Has Been Identified as One of the "Fastest Growing Companies in the Nordic Biotechnology Therapeutics & Diagnostics Industry"
Paras Biopharmaceuticals is pleased to announce that the company has been identified as one of the Fastest Growing Companies in the Nordic Biotechnology Therapeutics and Diagnostics industry by Plimsoll Publishing UK. - September 01, 2022 - Paras Biopharmaceuticals Finland Oy
Creative Diagnostics Launches Custom Virus Production Service
Creative Diagnostics has recently introduced the research community with customized virus production services. - August 26, 2022 - Creative Diagnostics
Creative Diagnostics Launches New Livestock Infectious Diseases Antigens
Creative Diagnostics announced the launch of more than 20 antigens for the development of veterinary infectious diseases diagnostics and vaccines. - August 26, 2022 - Creative Diagnostics
CABRI Announces Call for Proposals on Specialized Pro-Resolving Mediator Analytical Methods
The Cayman Biomedical Research Institute (CABRI) is offering research grants in amounts up to $100,000 to support essential research on specialized pro-resolving mediator (SPM) analytical methods. - August 26, 2022 - Cayman Chemical Company
Deadline Extended: CABRI Announces Undergraduate Fellowships and Scholarship Program
The Cayman Biomedical Research Institute (CABRI) is accepting applications from undergraduate students who have been offered an unpaid laboratory research position under an accredited principal investigator. Applications will be accepted from August 22 until September 18, 2022. - August 26, 2022 - Cayman Chemical Company
Pharma CI Conference Returns Next Month: Meet Hundreds of Industry Leaders at the Top Event for 15+ Years
Ready, set, engage! The Pharma CI USA Conference & Exhibition is back in person and ready to deliver the industry-leading experience that has made Pharma CI the gold standard event for more than fifteen years. The much-anticipated return happens this September 21-22 at the Newark Liberty... - August 18, 2022 - Pharma CI Conference
VMRD Begins Manufacturing Key Reagent for Detection of CWD by RT-QuIC
Veterinary Medical Research & Development (VMRD), Pullman, WA, has partnered with CWD Evolution, Fort Collins, CO, to provide state-of-the-art diagnostic reagents for detection of the abnormal prion associated with Chronic Wasting Disease (CWD). The control of CWD requires identification of... - August 09, 2022 - VMRD, Inc.
Peptineo, LLC Selected by EPA to Provide EPA Nationwide Coverage for Point of Care (POC) COVID-19 Testing
The Environmental Protection Agency (EPA), Cincinnati Acquisition Division (CAD), has awarded Peptineo LLC, an emerging aerospace, health services, and defense solutions company, a three-year Blanket Purchase Agreement (BPA) to support a comprehensive COVID-19 testing program in support of the... - August 07, 2022 - Peptineo
Creative Diagnostics Launches Monkeypox Virus Antibodies and Antigens to Support MPXV Research
Creative Diagnostics announced the launch of several Monkeypox Virus Antibodies and Antigens for the detection of Monkeypox viruses. - July 22, 2022 - Creative Diagnostics
Creative Diagnostics Introduces New Cell-Based ELISA Services
Creative Diagnostics is offering comprehensive services for Cell-based ELISA that can measure the reduction of viral antigens in infected cells using anti-virus antibodies or compounds. - July 22, 2022 - Creative Diagnostics
PharmStars Announces Spring 2022 Accelerator Graduates: 11 Digital Health Startups Have Successfully Completed PharmStars’ Pharma-Focused Accelerator Program
PharmStars, the pharma-focused accelerator for digital health startups, announces the graduation of 11 startups from its Spring 2022 program. The graduates successfully completed the 10-week PharmaU program, which culminated with the Showcase Event held June 8-10 in Boston. The Showcase Event brought together the participating startups and PharmStars’ seven innovation-minded pharma members. - July 12, 2022 - PharmStars
Global Cancer Technology Successfully Concludes Glioblastoma Pre-Clinical Animal Studies with Impressive Results
Global Cancer Technology, a San Diego, CA biotechnology company, has successfully completed animal testing with GCT.GLIO.1, a PI3K selective inhibitor that can cross the blood brain barrier and modulate immune cell function. The company will advance the compound to Phase 1 clinical trials as a next step. - July 08, 2022 - Global Cancer Technology
PharmStars Announces “Innovations in Real-World Evidence” Theme for Fall 2022 Accelerator
PharmStars, the pharma-focused accelerator for digital health startups, announces it is now accepting applications for its Fall 2022 cohort with the theme, “Innovations in Real-World Evidence.” - June 15, 2022 - PharmStars
Defined Bioscience Announces Formation of Scientific Advisory Board
Defined Bioscience, a life science tools company pioneering the development of next generation ingredients for cell culture, today announced the formation of its scientific advisory board (SAB). The SAB is comprised of a distinguished group of academic and industry experts who will advise the... - June 15, 2022 - Defined Bioscience Inc.
Creative Diagnostics Launches Measles Virus Antigens for the Detection of Antibodies
Creative Diagnostics announced the release of new measles virus antigens suitable for both IgM and IgG detection. - June 11, 2022 - Creative Diagnostics
Creative Diagnostics Introduces CC50/IC50 Assay Services for Pharmaceutical Safety
Creative Diagnostics introduced CC50/IC50 testing services with a high level of detection sensitivity and accuracy. - June 11, 2022 - Creative Diagnostics
PharmStars Announces Showcase Pitch Event for Spring 2022 Cohort
PharmStars, the pharma-focused accelerator for digital health startups, announces the start of its Showcase Event on June 8, 2022. The digital health startups that participated in the 10-week accelerator program will make formal presentations to, and answer questions from, the pharma members of PharmStars. All of PharmStars’ seven members are participating in the Showcase Event. - June 08, 2022 - PharmStars
Eledon Announces Phase 2a Trial Results of Tegoprubart (AT-1501) – a Drug Invented at ALS TDI
Eledon Pharmaceuticals announced topline results from their Phase 2 trial of tegoprubart (formerly AT1501), a drug invented and developed at the ALS Therapy Development Institute (ALS TDI). The Phase 2a trial in ALS was a 12-week, open label, dose escalating, safety, and biomarker study. The... - May 31, 2022 - ALS Therapy Development Institute
Scientific Reports Publishes Data Demonstrating VR Platform Produces Peak Experiences, Ego Attenuation & Connectedness Comparable to Moderate Dose Psychedelics
aNUma, Inc., a digital therapeutics company building virtual reality programs to address the global mental health crisis, today, announced that Scientific Reports has published research demonstrating technology like that behind aNUma’s VR platform can deliver peak experiences, ego attenuation, and connectedness comparable to psychedelics. This study, written by Dr. David Glowacki and colleagues, is the first of its kind to be published in a leading peer-reviewed journal. - May 30, 2022 - aNUma
Creative Diagnostics Launches Antibody-Dependent Enhancement Assay Services
Creative Diagnostics recently introduces comprehensive services for antibody-dependent enhancement (ADE) assay. - May 26, 2022 - Creative Diagnostics
Creative Diagnostics Announces Antigens for Epstein-Barr Virus Antibody Tests
Creative Diagnostics recently launched recombinant antigens p18 and p23 (viral capsid antigens, VCA), p54 and p138 (early antigens, EA) and EBNA1 (nuclear antigen, EBNA). - May 26, 2022 - Creative Diagnostics
ALS Therapy Development Institute Scientists to Present Posters Sharing Research Advancements at the ALS Drug Development Summit
The ALS TDI scientists will be showcasing significant advancements in ALS research through multiple poster presentations. These posters will cover pre-clinical research exploring potential new therapeutic drug-like molecules and targets for ALS, as well as translational research analyzing patient data to identify new ALS biomarkers, drug targets, and patient populations. - May 25, 2022 - ALS Therapy Development Institute
Molekule Consulting Announces the Launch of E.U. - Based Operations
Molekule Consulting announces the launch of an E.U. - based business / Molekule Hub continuing their focus on the development of global strategy and advisory services for the biopharmaceutical sector. - May 24, 2022 - Molekule Consulting
Biopharma Industry Standout Robert Proulx Joins Advisory Board of Global Cancer Technology
Global Cancer Technology is developing innovative treatments for deadly diseases like cancer, with a current focus on glioblastoma and breast cancer. To date, Mr. Robert Proulx has held numerous Board positions, is a recognized thought leader in biopharma, and currently holds dual roles as the founder and CEO of Imagion Biosystems. - May 21, 2022 - Global Cancer Technology
NuvOx Pharma Announces Issuance of a New Patent
NuvOx Pharma has been issued US Patent No. 11,304,899, entitled “Compositions of fluorocarbon nanoemulsion, and methods of preparation and use thereof.” - May 19, 2022 - NuvOx Therapeutics
NuvOx Appoints Dr. Robert King to SAB
NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, appointed Dr. Robert King to its Scientific Advisory Board (SAB). Dr. King is a seasoned life science executive with over 30 years’... - May 11, 2022 - NuvOx Therapeutics
The ALS TDI Discovery Biology Suite Dedicated in Honor of Liz Bodine to Speed Drug Development in ALS
The ALS Therapy Development Institute (ALS TDI) and Augie’s Quest to Cure ALS are proud to honor the commitment of Liz Bodine to facilitate more effective ALS drug discovery at ALS TDI, the world’s most comprehensive drug discovery lab dedicated solely to ALS. - May 04, 2022 - ALS Therapy Development Institute
Cyclists Support ALS Research with 3-Day, 270-Mile Ride from Boston to Greenwich in Tri-State Trek
Hundreds of riders to join the ride to end ALS this June and raise funds for cutting-edge ALS research. ALS TDI has received a $100,000 match for all donations made to the Tri-State Trek through the month of May. - May 03, 2022 - ALS Therapy Development Institute